Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PALEO: Phase II Clinical Trial of Chemoradioimmunotherapy for the ALleviation of oEsOphageal Cancer Complications

NCT06290505 is registered in ClinicalTrials.gov with Australasian Gastro-Intestinal Trials Group as lead sponsor.

NCT NCT06290505
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06290505 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PALEO: Phase II Clinical Trial of Chemoradioimmunotherapy for the ALleviation of oEsOphageal Cancer Complications
Lead sponsor
Australasian Gastro-Intestinal Trials Group
Phase
Phase 2
Overall status
Recruiting
Start date
December 8, 2021
Completion date
July 31, 2029
Enrollment
54 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer